Biomedical subjects
Stephen A Obstbaum
Publications and source records attributed to Stephen A Obstbaum.
White paper: Utilization, appropriate care, and quality of life for patients with cataracts.
Explore the source record for details and available documents.
Utilization, appropriate care, and quality of life for patients with cataracts: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, and European Society of Cataract and Refractive Surgeons.
Explore the source record for details and available documents.
The Gambian Eye Care Program.
Explore the source record for details and available documents.
Gold standard medical therapy for glaucoma: defining the criteria identifying measures for an evidence-based analysis.
BACKGROUND: Over the past decade, several new medical therapies have become available for the treatment of primary open-angle glaucoma (POAG). A systematic evidence-based approach for identifying an optimal therapeutic agent is lacking. OBJECTIVES: The aims of this review were to critically evaluate published treatment recommendations for POAG and, based on a systematic review of the literature, to develop criteria that would define a "gold standard" medical therapy that reflects new treatment advances and established therapeutic goals. METHODS: A MEDLINE search spanning the years 1966 to 2002 and using the search terms gold standard, drug of choice, agent of choice, benchmark, ophthalmology, eye, and glaucoma was conducted and the results reviewed by a panel of 15 experts in the field of glaucoma. Published treatment recommendations for POAG were discussed. Criteria, anchored to medical evidence, for distinguishing a standard of medical therapy for POAG were defined. RESULTS: The terms connoting a gold standard therapy were found in only 258 of approximately 368,000 ophthalmology-related citations and 53 of almost 23,000 glaucoma citations, validating the need to define therapeutic standards. The lack of recommendations for the use of new classes of ocular hypotensive agents was acknowledged. Criteria identified to evaluate intraocular pressure (IOP)-lowering agents as gold standards included the following: efficacy in reducing IOP consistently over a 24-hour period to a level that will preserve the visual field and protect the optic nerve without inducing tachyphylaxis and tolerance, paucity of local and systemic adverse effects, promotion of patient compliance, and applicability in diverse patient populations. CONCLUSIONS: These criteria should be employed as measures for evidence-based analyses to evaluate available and future IOP-lowering medical therapies for POAG. The conceptual framework presented may be applicable to other therapeutic areas.
Tracking our preferences: a 20-year view.
Explore the source record for details and available documents.
Emergence of the role of cataract and IOL surgery in the correction of refractive errors.
Explore the source record for details and available documents.